西安慧康企业运营管理集团有限公司(简称:慧康集团)成立于2012年。慧康集团以生物科技、美容连锁为核心业务集群,构建全产业链式的国际化企业运营体系,塑造生物科技应用于社会生活的核心价值。
慧康集团将商业实践与社会价值相融合,追求新产业时代下的可持续发展,斥资5亿元建设的生物科技产业园区,占地40亩,总建筑面积6.5万平方米,将科研、管理、培训、生产集于一体。截至2023年9月,慧康集团旗下子公司共有152项专利,包括国家发明专利75项、外观专利18项、实用新型专利29项,中国香港专利18项、国际专利12项;现有国家I类新药1项,医疗器械2项,西安市博士后创新基地项目3项,重点科研项目13项。
陕西慧康生物科技有限责任公司发起的“慧康•中国肽库”项目(简称“中国肽库”),将建立蛋白与多肽原料研发与供应基地,抢占“蓝海战略”引领下的价值创新高地。
HuiKang Culture
生物科技进化人类生活。
共创、共赢、共享。
为员工谋福利,为企业创价值,为社会做贡献。
知行合一,敬天爱人。
以人为本、以德为先、机会均等、任贤使能。
董事长 Chairman of the Board
中国资深媒体人,先后担任《重庆时报》《文化报》《华商报》等多家传媒高管及负责人,在任陕西华商报社党委书记、执行社长期间,通过创新产业运营模式,推进多元化经营与全媒体融合,率领华商报业创下历史最好业绩。
资本运营策略师,曾兼任多家上市公司战略决策顾问,首创“相氏系统管理环”公司战略与风险管理系统,长期致力于生物科技时代下新经济法则研究,人类进入生物文明时代倡言者。
Senior media editor in China. He has successively served as the senior executive and principal of many media companies, such as Chongqing Times, Cultural Daily and Huashang Daily. During his tenure as Party Secretary and executive president of Shaanxi Huashang Daily, he led Huashang Newspaper to achieve the best performance in history by innovating the industrial operation mode and promoting the integration of diversified operation & omnimedia convergence.
Capital Operations strategist. He doubled in many listed companies as a strategic counselor, initiated Corporate Strategy and Risk Management System, named "Xiang's System Management Loop", constantly strived to study the new economic laws in the era of biotechnology. He is an advocate of mankind entering the age of biological civilization.
董事 Board Member
发展生物科技,为社会做贡献,是孙剑先生信奉的宗旨。
近20年的经营中,他对大健康产业、生物科技具有非常执着的信念、前瞻的战略眼光、卓越的运营能力,以及丰富的管理经验。
2010年,他基于蛋白与多肽的应用研究,投资发展生物科技大健康业务。目前,已建设并投入使用65000平米慧康生物产业园,配备国际先进的科研以及生产设备、经营范围涵盖新药、基因治疗、医疗器械以及化妆品的研发、生产与销售。
Developing biotechnology and making contributions to society are Mr. Sun’s beliefs.
From nearly 20 years of operation, he got a firm conviction in the massive health industry and biotechnology, along with forward-looking strategic vision, excellent operational capabilities and rich management experience.
In 2010, he invested in the massive health industry based on applied research in proteins and peptides. At present, a 65,000 m2 HuiKang Biological Industrial Park has been built and put into operation with international advanced scientific research and production equipment. The business scope covers the R&D of new drugs, gene therapy, medical devices and the R&D, manufacture and sales of cosmetics.
2021
Huikang Bio-Tech was the only Chinese enterprise in the new material group of the Global Top 100 Innovative list.
2021
Huikang Bio-Tech was subsidize by the State Key Laboratory of Mechanical Behavior of Materials, Ministry of Education.
2021
HuiKang Novel Coronavirus blocking peptide project obtained class I fund of Postdoctoral Innovation Base.
2020
Argireline Serum received the honor of Shaanxi Key New Products.
2020
The scientific achievements of collagen have been published in famous academic journal International Journal of Biological Macromolecules.
2020
The brand ACTII was born.
2019
HuiKang Biotechnology Industrial Park officially put into operation.
2018
Successfully hosted the International Protein and Peptides Conference, a sub forum of the 2018 Global Hard and Core Conference and the Belt and Road Innovation conference.
2018
Introduction article of HuiKang • China Peptide Bank published in the sub Journal of Nature.
2017
Launched the Phase I Construction Plan of HuiKang• China Peptide Bank.
2017
Started Bio-tech cosmetics business.
2017
The bio-tech cosmetics brand Ye New Skin was debuted.
2016
Initiate the R&D of two national class I new drugs.
2012
Xi 'an HuiKang Enterprise Operation Management Group Co., LTD was founded.
2012
Obtained the first national invention patent.
2011
HuiKang Biotechnology Industrial Park broke groud and started building.
2011
A series of skin care products with protein and peptides as the core ingredients have came out after one and another..
2011
Recombinant human collagen was successfully developed..
2010
HuiKang R&D Center was set up.
2001
Shaanxi Dongda Biochemical Technology Co., LTD. (the predecessor of HuiKang Bio-Tech) was established.
截至2022年10月底,慧康集团旗下子公司共有134项专利,包括国家发明专利65项、外观专利17项、实用新型专利25项,中国香港专利12项、 国际专利15项。
投资5.2亿元,占地42亩,建筑面积6.5万平方米。
合成多肽中试放大系统
蛋白多肽制剂中试放大生产系统
重组蛋白中试放大生产系统
“中国肽库”项目计划构建一个序列精准的商业肽库,或称平行肽库,共计超过175000条肽,未来将成为人类共享的宝库。
Copyright © 2017 慧康集团保留所有权利/
陕ICP备17008662号-1友情链接:
慧康生物研发中心